Preferred Initial Test for Diagnosing Influenza in High-Risk Patients
For high-risk outpatients (young children, pregnant women, older adults, or those with chronic conditions), use rapid molecular assays (nucleic acid amplification tests/NAATs) as the preferred initial diagnostic test, while rapid influenza diagnostic tests (RIDTs) are acceptable alternatives when molecular assays are unavailable. 1
Test Selection by Clinical Setting
Outpatient High-Risk Patients
- First choice: Rapid molecular assays (NAATs) provide superior sensitivity and specificity compared to other point-of-care options 1
- Acceptable alternative: Rapid influenza diagnostic tests (RIDTs) can be used in outpatient settings to improve detection, though they have lower sensitivity 1
- Timing: Collect specimens as soon as possible, preferably within 4 days of symptom onset 1
Hospitalized High-Risk Patients
- Mandatory test: RT-PCR or other molecular assays should be used over all other influenza tests 1
- Do NOT use: RIDTs or immunofluorescence assays in hospitalized patients except when molecular assays are unavailable 1
- Critical caveat: If RIDTs or immunofluorescence tests are initially used and return negative, follow-up testing with RT-PCR or molecular assays must be performed to confirm results 1
Specimen Collection Hierarchy
The quality of your specimen directly impacts test accuracy. Follow this priority order:
- Best: Nasopharyngeal specimens (highest viral detection) 1
- Second best: Combined nasal and throat swabs (better than single specimens) 1
- Third option: Mid-turbinate nasal swabs (superior to throat swabs alone) 1
- Technical detail: Use flocked swabs over non-flocked swabs 1
Special Considerations for High-Risk Populations
When to Test High-Risk Patients
During influenza season, test high-risk patients who present with:
- Influenza-like illness, pneumonia, or even nonspecific respiratory symptoms (cough without fever) 1
- Acute worsening of chronic conditions (asthma, COPD, heart failure, coronary artery disease) 1
- Any acute respiratory symptoms if immunocompromised, as manifestations may be atypical 1
Why Molecular Tests Matter for High-Risk Patients
The IDSA guidelines explicitly state that RT-PCR and molecular assays should be prioritized in hospitalized patients because they offer significantly better sensitivity than RIDTs 1. This is critical for high-risk patients where missing a diagnosis could lead to delayed antiviral treatment and increased morbidity/mortality. The guidelines note that RIDTs have insufficient sensitivity for hospitalized patients, and negative results cannot be trusted to rule out influenza 1.
Common Pitfalls to Avoid
- Never rely on RIDTs alone in hospitalized high-risk patients - their lower sensitivity means you'll miss cases 1
- Don't use serologic testing for acute diagnosis - it requires paired sera 2-3 weeks apart and won't inform immediate clinical decisions 1
- Don't test non-respiratory sites (blood, CSF, urine, stool) - these are not useful for influenza diagnosis 1
- Don't delay antiviral treatment waiting for test results in severely ill high-risk patients - start empiric treatment if clinical suspicion is high 2
Integration with Treatment Decisions
Recent WHO guidelines recommend diagnostic testing strategies that enable rapid treatment decisions 3, 4. For high-risk non-severe cases, rapid testing followed by immediate antiviral treatment if positive optimizes outcomes 5. The benefit of antiviral treatment is greatest when started within 24 hours of symptom onset 6, making rapid, accurate diagnosis essential for high-risk populations.